bluebird bio, Inc. (NASDAQ: BLUE)

This lawsuit is for anyone who acquired securities in bluebird bio, Inc. (NASDAQ: BLUE) from April 24, 2023 through December 8, 2023.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the FDA would approve the Company’s gene therapy drug, Lyfgenia, without any black box warnings when the Company knew that the FDA would require black box warnings.

On December 8, 2023, bluebird announced that it had received approval from the FDA for its ex-vivo gene therapy drug Lyfgenia for sickle cell disease. Along with the approval came a black box warning for haematological malignancies with a requirement to monitor patients for cancer through complete blood counts at least every six months for at least 15 years, plus viral vector integration site analysis every six months as warranted. Additionally, the Company’s anticipated priority review voucher was denied by the FDA. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in bluebird bio, Inc. (NASDAQ: BLUE) from April 24, 2023 through December 8, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.